From: Consensus clinical management guidelines for Niemann-Pick disease type C
Recommended assessment | Rationale | Frequency | References |
---|---|---|---|
Baseline history | Establish current level of disease severity and retrospectively estimate rate of progression | At diagnosis | |
Interval history | Establish rate of disease progression; monitor for compliance with and side effects from therapy; monitor for conditions which would prompt discontinuation of therapy | 6Â months | |
Physical examination | Document growth parameters, assess for neurological features and organomegaly | At diagnosis then every 6–12 months | |
NPC clinical severity score | Document key features of disease at diagnosis, progression and response to therapy | At diagnosis and then every 6Â months | |
Neuropsychiatric evaluation | Document and treat psychiatric manifestations and response to therapy | At diagnosis then every 6–12 months | |
Developmental or cognitive assessment | Document baseline degree of cognitive impairment and monitor response to therapy | At diagnosis; every 6Â months in children; every 12Â months in adults | |
Ophthalmology evaluation | Document saccadic eye movement velocity and presence of gaze palsy at baseline and document response to miglustat therapy in treated patients | At diagnosis; at 6 and 12Â months; after starting treatment; frequency after 12Â months can be determined by clinical response | [61] |
Audiometry | Document presence of hearing loss | At diagnosis then every 12Â months | [81] |
Swallowing assessment | Clinical swallowing assessment in all patients; videofluoroscopic swallowing (VFS) assessment may be useful in some patients; Document presence of dysphagia and aspiration and response to therapy | At diagnosis and then every 6Â months in children; in adults, frequency could be reduced to every 12Â months if asymptomatic and disease is stable | |
Neuroimaging | Magnetic resonance imaging or more detailed forms of neuroimaging including MR spectroscopy and diffusion tensor imaging | At baseline if available; Decisions about follow up neuroimaging will depend on local availability and need for general anaesthesia |